Literature DB >> 7599109

Protein-free culture of the human pancreatic cancer cell line, SUIT-2.

S Taniguchi1, T Iwamura, N Kitamura, H Yamanari, A Kojima, K Hidaka, K Seguchi, T Setoguchi.   

Abstract

A human pancreatic cancer cell line (SUIT-2), usually cultured in serum-supplemented medium (DMEM/FBS), was adapted to protein-free conditions using a 1:1 mixture of DMEM and Ham's F12 medium (DMEM/F12). The cells have been maintained in DMEM/F12 for more than 2 years, with over 50 passages. The SUIT-2 cells grew in DMEM/F12 with a doubling time of 35.7 h, which was similar to that in DMEM/FBS (35.0 h). The cellular morphology was similar in both media. Type IV collagenolytic activity was detected in the conditioned media from cells grown in DMEM/F12. The secretion of CEA and CA19-9 initially decreased in DMEM/F12. CEA was not detected after passage 5 (p5) but the concentration of CA19-9 did not decrease further after the first few serial passages in protein-free medium. Xenografts of SUIT-2 cells cultured in DMEM/F12 remained tumorigenic and could form metastatic tumors in nude mice. In conclusion, SUIT-2 cells grown in protein-free media continued to produce CA19-9 and type IV collagenase in vitro and formed metastatic tumors in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7599109

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  2 in total

1.  Establishment and characterization of SUIT-58 pancreas cancer cell line and its subline S58-SF adapted to serum-free condition derived from metastatic liver tumor.

Authors:  Nobuyasu Takahashi; Fumiyo Aoyama; Jiro Ohuchida; Naoki Sameshima; Yujiro Asada; Akira Sawaguchi
Journal:  Hum Cell       Date:  2015-07-04       Impact factor: 4.174

2.  Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient.

Authors:  Panthip Rattanasinganchan; Kawin Leelawat; Sa-ard Treepongkaruna; Chintana Tocharoentanaphol; Somboon Subwongcharoen; Tuangporn Suthiphongchai; Rutaiwan Tohtong
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.